Obesity and inflammation: Change in adiponectin, C-reactive protein, tumour necrosis factor-alpha and interleukin-6 after bariatric surgery

Obesity Surgery

Volumn 22, Issue 6, 2012, Pages 950-955

  Illán Gómez, Fátima ^a   Gonzálvez Ortega, Manuel ^a   Orea Soler, Isabel ^a   Alcaraz Tafalla, Ma Soledad ^a   Aragón Alonso, Aurora ^a   Pascual Díaz, Mercedes ^a   Pérez Paredes, Matías ^a   Lozano Almela, Ma Luisa ^a  

^a HOSPITAL MORALES MESEGUER   (Spain)

Author keywords

Adiponectin; Bariatric surgery; hs CRP; IL 6; Inflammation; Insulin resistance; Obesity; TNF

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BARIATRIC SURGERY; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HOMEOSTASIS; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORBID OBESITY; OPERATION DURATION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; WEIGHT REDUCTION;

ADIPONECTIN; ADULT; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; COHORT STUDIES; FEMALE; GASTRIC BYPASS; HUMANS; INFLAMMATION; INTERLEUKIN-6; OBESITY, MORBID; TUMOR NECROSIS FACTOR-ALPHA; WEIGHT LOSS;

EID: 84862612940     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-012-0643-y     Document Type: Article

References (47)

1. Wexler Dj, Hu FB, Manson JE. Mediating effects of inflammatory biomarkers on insulin resistance associated with obesity. Obes Res. 2005;13:1772-83.
2. Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27000 participants from 52 countries: a case-control study. Lancet. 2005;366:1640-9.
3. Hubert HB, Feinleib M, McNamara PM, et al. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67:968-77.
4. Guerre Millo M. Adipose tissue and adipokines for better or worse. Diabetes Metab. 2004;30:13-9.
5. Trayhum P, Wood IS. Signalling role of adipose tissue: adipokines and inflammation in obesity. Biochem Soc Trans. 2005;33:1078-81.
6. Winkler G, Kiss S, Keszthelyi L. Expression of tumor necrosis factor (TNF)-alpha protein in the subcutaneous and visceral adipose tissue in correlation with adipocyte cell volume, serum TNF-alpha, soluble serum TNF-receptor-2 concentrations and C-peptide level. Eur J Endocrinol. 2003;149:129-35.
7. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Inmunol. 2006;6:772-83.
8. Guerre Millo M. Adiponectin: an update. Diabetes Metab. 2008;34:12-8.
9. Hager GR, van Haeten TW, Visseren FLJ. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J. 2008;29:2959-71.
10. Pischon T, Girman CJ, Hotamisligil GS, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291:1730-7.
11. Kumada M, Kihara S, Sumitsuji S, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003;23:85-9.
12. Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98:731-3.
13. Ridker PM, Brown NJ, Vaughan DE. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation. 2004;109(25):IV6-19. Suppl 1.
14. Brolin RE. Bariatric surgery and long-term control of morbid obesity. JAMA. 2002;288:2793-6.
15. Sjöström L, Lindroos A, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351(26):2683-93.
16. Scheen AJ, Letiexhe M, Rorive M, et al. Bariatric surgery: 10-year results of the Swedish Obese Subjects Study. Rev Méd Liège. 2005;60(2):121-5.
17. Sugerman HJ, Wolfe LG, Sica DA. Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss. Ann Surg. 2003;237(6):751-8.
18. Buchwald H. Bariatric surgery: a systematic review and metaanalysis. JAMA. 2004;292(14):1724-37.
19. Capella RF, Capella JF. Reducing early technical complications in gastric by-pass surgery. Obes Surg. 1997;7:149-57.
20. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia. 1985;28:412-9.
21. Compher C, Badellino KO. Obesity and inflammation: lessons from bariatric surgery. JPEN. 2008;32:645-7.
22. Vazquez LA, Pazos F, Berrazueta JR, et al. Effects of changes in body weight and insulin resistance on inflammation and endothelial function in morbid obesity after bariatric surgery. J Clin Endocrinol Metab. 2005;90:316-22.
23. Vilarrasa N, Vendrell J, Sanchez-Santost R. Effect of weight loss induced by gastric bypass on proinflammatory interleukin-18, soluble tumour necrosis factor-α receptors, C-reactive protein and adiponectin in morbidly obese patients. Clin Endocrinol. 2007;67:679-86.
24. Forsythe LK, Wallace JMW, Livingstone MBE. Obesity and inflammation: the effects of weight loss. Nutr Res Rev. 2008;21:117-33.
25. Butner KL, Nickols-Richardson SM, Clark SF, et al. A review of weight loss following Roux-en-Y gastric bypass vs restrictive bariatric surgery: impact on adiponectin and insulin. Obes Surg. 2010;20:559-68.
26. Garcia de la Torre N, Rubio MA, Bordiú E. Effects of weight loss after bariatric surgery for morbid obesity on vascular endothelial growth factor-A, adipocytokines, and insulin. J Clin Endocrinol Metab. 2008;93:4276-81.
27. Trakhtenbroit MA, Leichman JG, Algahim MF, et al. Body weight, insulin resistance, and serum adipokine levels two years after two types of bariatric surgery. Am J Med. 2009;122:435-42.
28. Swarbrick MM, Stanhope KL, Austrheim-Smith IT, et al. Longitudinal changes in pancreatic and adipocyte hormones following Roux-en-Y gastric bypass surgery. Diabetologia. 2008;51:1901-11.
29. Dandona P. Tumor necrosis factor-α in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab. 1998;83(8):2907-10.
30. Cottam DR, Mattar SG, Barinas-Mitchell E, et al. The chronic inflammatory hypothesis for the morbidity associated with morbid obesity: implications and effects of weight loss. Obes Surg. 2004;14(5):589-600.
31. Kopp H. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol. 2003;23(6):1042-7.
32. Vazquez LA, Pazos F, Berrezueta JR, et al. Effects of changes in body weight and insulin resistance on inflammation and endothelial function in morbid obesity after bariatric surgery. J Clin Endocrinol Metab. 2005;90(1):316-22.
33. Appachi S, Kelly KR, Schauer PR, et al. Reduced cardiovascular risk following bariatric surgeries is related to a partial recovery from "adiposopathy". Obes Surg. 2011;21:1928-36.
34. Whitson B, Leslie D, Kellogg T, et al. Adipokine response in diabetics and nondiabetics following the Roux-en-Y gastric bypass: a preliminary study. J Surg Res. 2007;142(2):295-300.
35. Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo. J Clin Endocrinol Metab. 1997;82:4196-200.
36. Mohamed-Ali V, Goodrick S, Bulmer K, et al. Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. Am J Physiol. 1999;277:E971-5.
37. Hauner H, Bender M, Haastert B, et al. Plasma concentrations of soluble TNF-alpha receptors in obese subjects. Int J Obes Relat Metab Disord. 1998;22(12):1239-43.
38. Fernández-Real JM, Broch M, Ricart W, et al. Plasma levels of the soluble fraction of tumor necrosis factor receptor-2 and insulin resistance. Diabetes. 1998;47:1752-62.
39. Straczkowski M, Kowalska I, Stepien A. Increased plasma soluble tumor necrosis factor-2 receptor level in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes Cares. 2002;25(10):1824-8.
40. Bluher M, Kratzsch J, Paschke R. Plasma levels of TNF-α, angiotensin II, growth hormone, and IGF-I are not elevated in insulin-resistant obese individuals with impaired glucose tolerance. Diabetes Care. 2001;24:328-34.
41. Zittermann A. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol. 2003;41(1):105-12.
42. Bloomberg RD, Fleishman A, Nalle JE, et al. Nutritional deficiencies following bariatric surgery: what have we learned? Obes Surg. 2005;15(2):145-54.
43. Kim KY, Kim JK, Han SH, et al. Adiponectin is a negative regulator of NK cell cytotoxicity. J Immunol. 2006;176:5958-64.
44. Chen H, Montagnani M, Funahashi T, et al. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem. 2003;278:45021-6.
45. Haque WA, Shimomura I, Matsuzawa Y, et al. Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab. 2002;87:2395.
46. Weyer C, Funahashi T. Tanaka S et al Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86:1930-5.
47. Cowan GS, Buffington CK. Significant changes in blood pressure, glucose, and lipids with gastric bypass surgery. World J Surg. 1998;22:987-92.